Profund Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-81,190
| Closed | -$3.27M | – | 1182 |
|
|
2026
Q1 | $3.27M | Buy |
81,190
+19,358
| +31% | +$417K | 0.12% | 121 |
|
|
2025
Q4 | $1.55M | Buy |
61,832
+27,120
| +78% | +$636K | 0.05% | 264 |
|
|
2025
Q3 | $786K | Buy |
34,712
+6,036
| +21% | +$141K | 0.03% | 382 |
|
|
2025
Q2 | $496K | Sell |
28,676
-6,981
| -20% | -$129K | 0.02% | 465 |
|
|
2025
Q1 | $780K | Sell |
35,657
-8,662
| -20% | -$239K | 0.03% | 352 |
|
|
2024
Q4 | $1.41M | Buy |
44,319
+5,705
| +15% | +$172K | 0.05% | 241 |
|
|
2024
Q3 | $1.11M | Sell |
38,614
-4,354
| -10% | -$161K | 0.04% | 297 |
|
|
2024
Q2 | $1.65M | Buy |
42,968
+20,435
| +91% | +$925K | 0.06% | 207 |
|
|
2024
Q1 | $1.32M | Sell |
22,533
-25
| -0.1% | -$1.59K | 0.05% | 278 |
|
|
2023
Q4 | $1.35M | Sell |
22,558
-12,595
| -36% | -$639K | 0.06% | 267 |
|
|
2023
Q3 | $1.34M | Buy |
35,153
+18,766
| +115% | +$824K | 0.07% | 223 |
|
|
2023
Q2 | $1.49M | Sell |
16,387
-5,307
| -24% | -$458K | 0.08% | 206 |
|
|
2023
Q1 | $1.43M | Buy |
21,694
+8,972
| +71% | +$518K | 0.09% | 193 |
|
|
2022
Q4 | $658K | Buy |
12,722
+315
| +3% | +$16.7K | 0.04% | 353 |
|
|
2022
Q3 | $847K | Buy |
+12,407
| New | +$734K | 0.06% | 271 |
|
Other funds holding APLS
Profund Advisors's APLS Position: Q2 2026 in Review
Profund Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 81,190 shares — an estimated $3.27M sold.
Profund Advisors first reported a position in APLS in Q3 2022 and held it in 15 quarters. The position peaked at $3.27M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Profund Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Profund Advisors sold 81,190 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.27M.
- Profund Advisors first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 15 quarters.
- Profund Advisors's Apellis Pharmaceuticals position peaked at $3.27M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.